Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Frequently asked questions
What sector does Bioceltix S.A. (BCX) operate in?
Bioceltix S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Bioceltix S.A. (BCX) current stock price?
As of the latest data, Bioceltix S.A. stock price is PLN 80.60, with a previous close of PLN 81.80. Bioceltix S.A. lost -PLN 1.20 in the last trading session, representing a -1.47% loss.
What is Bioceltix S.A. (BCX) current market capitalization?
Bioceltix S.A. market cap is approximately 445.90 million.
What is Bioceltix S.A. (BCX) Earnings Per Share (EPS)?
The trailing EPS is -PLN 3.29, and the forward EPS is -PLN 1.90.
What is Bioceltix S.A. (BCX) EBITDA?
Bioceltix S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.99 million.
Does Bioceltix S.A. (BCX) pay dividends?
No. Bioceltix S.A. does not pay a dividend.
What is Bioceltix S.A. (BCX) beta (volatility) score?
Bioceltix S.A. has a beta of 0.919, meaning its volatility is roughly in line with the market.
